文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

达普司他治疗透析患者贫血的研究

Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis.
PubMed 文献 · N Engl J Med · 2021-11-05
一句话结论在透析的慢性肾脏病患者中,口服达普司他在血红蛋白变化和心血管结局方面不劣于促红细胞生成素类药物。

这项随机、开放标签、3期试验纳入2964例接受透析且血红蛋白8.0至11.5 g/dL的慢性肾脏病患者,比较口服HIF-PHI达普司他与注射促红细胞生成素类药物(血液透析用阿法依泊汀,腹膜透析用阿法达贝泊汀)。从基线至第28至52周血红蛋白平均变化:达普司他组0.28±0.02 g/dL,ESA组0.10±0.02 g/dL,差异0.18 g/dL(95%CI 0.12至0.24),达到预设非劣效界值-0.75 g/dL。中位随访2.5年,主要不良心血管事件发生率达普司他组25.2%(374/1487) vs ESA组26.7%(394/1477),HR 0.93(95%CI 0.81至1.07),达到预设非劣效界值1.25。两组其他不良事件发生率相似。

要点

  • 在透析的CKD患者中,口服达普司他组从基线至第28至52周血红蛋白平均变化为0.28±0.02 g/dL,ESA组为0.10±0.02 g/dL,差异0.18 g/dL(95%CI 0.12至0.24),达到非劣效界值-0.75 g/dL。
  • 中位随访2.5年,达普司他组主要不良心血管事件发生率为25.2%(374/1487),ESA组为26.7%(394/1477),HR 0.93(95%CI 0.81至1.07),达到非劣效界值1.25。
  • 两组其他不良事件发生率相似。
  • 研究纳入接受透析且血红蛋白8.0至11.5 g/dL的CKD患者;血液透析者对照为阿法依泊汀,腹膜透析者对照为阿法达贝泊汀。

适用人群与场景

  • 接受透析的慢性肾脏病患者,血红蛋白水平为8.0至11.5 g/dL。
  • 血液透析患者对照使用阿法依泊汀;腹膜透析患者对照使用阿法达贝泊汀。

处置流程与药物剂量

  • 口服HIF-PHI达普司他,对照为注射ESA(血液透析用阿法依泊汀,腹膜透析用阿法达贝泊汀)。
  • 血红蛋白目标为从基线至第28至52周的平均变化,非劣效界值为-0.75 g/dL。
  • 主要不良心血管事件非劣效界值为1.25。

研究设计与关键结果

  • 随机、开放标签、3期试验,共2964例患者接受随机化;总体平均(±SD)基线血红蛋白为10.4±1.0 g/dL。
  • 从基线至第28至52周血红蛋白平均(±SE)变化:达普司他组0.28±0.02 g/dL,ESA组0.10±0.02 g/dL,差异0.18 g/dL(95%CI 0.12至0.24),达到预设非劣效界值-0.75 g/dL。
  • 中位随访2.5年,主要不良心血管事件(全因死亡、非致死性心肌梗死或非致死性卒中的复合终点)首次发生:达普司他组374/1487例(25.2%),ESA组394/1477例(26.7%),HR 0.93(95%CI 0.81至1.07),达到预设非劣效界值1.25。
  • 两组其他不良事件发生率相似。

证据类型、等级与局限

  • 随机、开放标签、3期试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在透析的CKD患者中,口服达普司他在血红蛋白变化和心血管结局方面不劣于ESA,可能为贫血管理提供口服替代方案。
  • 使用达普司他时需关注主要不良心血管事件,但本研究显示与ESA相比未增加风险(HR 0.93,95%CI 0.81至1.07)。

指南或共识出处

  • ASCEND-D试验(ClinicalTrials.gov编号NCT02879305),由葛兰素史克资助。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Among patients with chronic kidney disease (CKD), the use of recombinant human erythropoietin and its derivatives for the treatment of anemia has been linked to a possibly increased risk of stroke, myocardial infarction, and other adverse events. Several trials have suggested that hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitors (PHIs) are as effective as erythropoiesis-stimulating agents (ESAs) in increasing hemoglobin levels.

METHODS: In this randomized, open-label, phase 3 trial, we assigned patients with CKD who were undergoing dialysis and who had a hemoglobin level of 8.0 to 11.5 g per deciliter to receive an oral HIF-PHI (daprodustat) or an injectable ESA (epoetin alfa if they were receiving hemodialysis or darbepoetin alfa if they were receiving peritoneal dialysis). The two primary outcomes were the mean change in the hemoglobin level from baseline to weeks 28 through 52 (noninferiority margin, -0.75 g per deciliter) and the first occurrence of a major adverse cardiovascular event (a composite of death from any cause, nonfatal myocardial infarction, or nonfatal stroke), with a noninferiority margin of 1.25.

RESULTS: A total of 2964 patients underwent randomization. The mean (±SD) baseline hemoglobin level was 10.4±1.0 g per deciliter overall. The mean (±SE) change in the hemoglobin level from baseline to weeks 28 through 52 was 0.28±0.02 g per deciliter in the daprodustat group and 0.10±0.02 g per deciliter in the ESA group (difference, 0.18 g per deciliter; 95% confidence interval [CI], 0.12 to 0.24), which met the prespecified noninferiority margin of -0.75 g per deciliter. During a median follow-up of 2.5 years, a major adverse cardiovascular event occurred in 374 of 1487 patients (25.2%) in the daprodustat group and in 394 of 1477 (26.7%) in the ESA group (hazard ratio, 0.93; 95% CI, 0.81 to 1.07), which also met the prespecified noninferiority margin for daprodustat. The percentages of patients with other adverse events were similar in the two groups.

CONCLUSIONS: Among patients with CKD undergoing dialysis, daprodustat was noninferior to ESAs regarding the change in the hemoglobin level from baseline and cardiovascular outcomes. (Funded by GlaxoSmithKline; ASCEND-D ClinicalTrials.gov number, NCT02879305.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Singh AK, Carroll K, Perkovic V, et al. Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis. N Engl J Med. 2021. PMID: 34739194. doi:10.1056/NEJMoa2113379

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。